IA Mayer

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat et al. · Annals of Oncology · 2020 · 140 citations · Full text

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Dejan Juric, Eva Ciruelos, Gábor Rubovszky et al. · Cancer Research · 2019 · 62 citations

Breast Oncology, Pathology, Overall Survival +16

Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

Dejan Juric, Roohi Ismail‐Khan, Mario Campone et al. · Cancer Research · 2016 · 36 citations

Breast Oncology, Cancer Biology, Tumor Biology +19

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

MN Dickler, JA Perez Fidalgo, IA Mayer et al. · Cancer Research · 2018 · 30 citations

Breast Oncology, Gdc-0927 Exposure, Estrogen Receptor +20

A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.

IA Mayer, Howard A. Burris, Johanna C. Bendell et al. · Cancer Research · 2009 · 19 citations

Weekly Cisplatin, Basal-like Breast Cancers, Breast Oncology +13